Crescendo Biologics Limited

We are pleased to share details from a paper co-authored by Crescendo scientists and the Resolian team, published earlier this week in Bioanalysis Zone. In the development of novel therapeutics, establishing robust and reliable assays to understand the pharmacokinetic (PK) properties of a drug in patients is crucial. Bispecific antibody fragments present unique challenges due to the multiple targets and often reduced molecular size, which increases the complexity of assay development.   Our scientists have developed a method to quantify CB307, our first-in-class Humabody® VH bispecific targeting PSMA and CD137 in blood. This method is already being used to support our Phase 1b POTENTIA clinical trial. In this paper, we share our findings and the method development process as a case study to help the broader scientific community overcome similar challenges in developing antibody fragment-based therapeutics.   To read the full paper, visit: https://lnkd.in/e9Z-vpZN   #Cancer #Biotech #Therapeutics

Our scientists along with Professor Greg Thurber’s laboratory, including Dr Anna Kopp at the University of Michigan Chemical Engineering have co-written a paper recently published in The AAPS Journal, on the functional design of immune cell targeting therapeutics.   The paper demonstrates the importance of fine-tuning features such as affinity, valency, linker length, in the context of target receptor expression on tumour or immune cells. The results in the paper further highlight the flexibility and modularity of our Humabody VH platform, as well as the importance of the careful consideration given by our expert team to the design of these molecules.   This paper marks the successful culmination of another chapter of our productive collaboration with Professor Greg Thurber and his team.   To read the full paper, visit: https://lnkd.in/ezzwY989   #Biotech #Therapeutics #Discovery

We are excited to announce that our partner Zai Lab has dosed its first patient in a global Phase 2 clinical trial evaluating the efficacy and safety of the IL-17 targeted therapy ZL-1102 for the topical treatment of chronic plaque psoriasis.   Crescendo granted Zai Lab an exclusive global license for ZL-1102 in May 2018. The preceding Phase 1b study resulted in the declaration of clinical proof-of-concept, where Humabody® VH became the first biologic to penetrate psoriatic skin and result in a clinical benefit.   This topical immune-modulating therapy highlights opportunities for new treatment modalities for patients, and further supports the strength of Crescendo’s Humabody® platform beyond systemic administration. We look forward to closely following the Phase 2 trial’s progress.   Read the full press release here: https://lnkd.in/eXG_y7a4   #Immunology #Biotech #Therapeutics #Partnership

Our Associate Director of Business Development Amanda You will be attending the BIO International Convention in San Diego, California from 3-6 June. She will be meeting partners and peers to discuss Crescendo’s therapeutic pipeline and other insights. To arrange a meeting with her, please do not hesitate to reach out on the partnering platform. #BIO2024 #Cancer #Biotech #Therapeutics

Our Chief Medical Officer Dr Kenji Hashimoto and Chief Development Officer Dr Phil Bland-Ward will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 31 May – 4 June in Chicago.   Kenji and Phil are looking forward to networking with fellow oncology professionals, sharing updates from Crescendo’s Humabody® therapeutic pipeline, as well as hearing about the latest clinical advancements in the cancer field.   To arrange a meeting with the team, contact: investors@crescendobiologics.com   #Cancer #Biotech #Therapeutics #ASCO24

Last night, Crescendo attended the Cambridge Independent #Science and #Technology Awards. As our CEO Theodora Harold shared below, it is truly an honour to be a part of the Cambridge scientific ecosystem. https://lnkd.in/eagEYxaV

Many thanks to everyone who joined our poster presentations at AACR yesterday. We are thrilled to be simultaneously publishing preclinical data for our lead programme, CB307, in Clinical Cancer Research, including our collaborative work with The Institute of Cancer Research, London   Learn more here (https://lnkd.in/e5hwKeWQ)

Join our VP Translational Biology Andrew Pierce and Senior Scientist Phillip Brailey, who will be presenting two posters during the Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April.   To find out more details on the abstracts, visit https://lnkd.in/dsDTgZq   #Cancer #Biotech #AACR

We are delighted to be a finalist for 'Biotech of the Year' at this year's Cambridge Independent #Science and #Technology Awards. Our CEO, Theodora Harold, has also been nominated for 'CEO of the Year'. This recognition is especially honouring for Crescendo Biologics given the history and culture of cutting-edge scientific breakthroughs made in Cambridge, a scientific community we are proud to be a part of.   To read the full nomination list: https://lnkd.in/eKGyYYdS   #SciTechAwards #Cambridge #Immunooncology

We are pleased to be attending BIO-Europe Spring 2024 on 18-20 March in Barcelona. If you would like to meet us to discuss our Humabody® platform or T cell enhancing pipeline, please reach out to us via the partnering platform - we look forward to speaking with you. #biopharma #BIOEuropeSpring #immunooncology